JP2005528332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528332A5 JP2005528332A5 JP2003550718A JP2003550718A JP2005528332A5 JP 2005528332 A5 JP2005528332 A5 JP 2005528332A5 JP 2003550718 A JP2003550718 A JP 2003550718A JP 2003550718 A JP2003550718 A JP 2003550718A JP 2005528332 A5 JP2005528332 A5 JP 2005528332A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- mycobacterium
- component
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 241001494992 Mycobacterium indicus pranii Species 0.000 claims 16
- 230000000694 effects Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000004094 surface-active agent Substances 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical group ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 238000000053 physical method Methods 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 108010046334 Urease Proteins 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1167MU2001 | 2001-12-10 | ||
| PCT/IB2002/005516 WO2003049667A2 (en) | 2001-12-10 | 2002-12-10 | The method of treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005528332A JP2005528332A (ja) | 2005-09-22 |
| JP2005528332A5 true JP2005528332A5 (enExample) | 2006-01-05 |
| JP4527979B2 JP4527979B2 (ja) | 2010-08-18 |
Family
ID=11097334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003550718A Expired - Fee Related JP4527979B2 (ja) | 2001-12-10 | 2002-12-10 | 癌を治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7972609B2 (enExample) |
| JP (1) | JP4527979B2 (enExample) |
| AP (1) | AP1896A (enExample) |
| AU (1) | AU2002348738B2 (enExample) |
| CA (1) | CA2469266C (enExample) |
| GB (1) | GB2389532C (enExample) |
| NZ (1) | NZ533417A (enExample) |
| UA (1) | UA79952C2 (enExample) |
| WO (1) | WO2003049667A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1948782T3 (pl) | 2005-04-25 | 2013-01-31 | Cadila Pharmaceuticals Ltd | Adiuwanty szczepionki |
| GB2464231B (en) * | 2006-11-23 | 2010-08-04 | Cadila Pharmaceuticals Ltd | Poly-TLR antagonist |
| CA2681420A1 (en) * | 2007-03-20 | 2008-09-25 | Cadila Pharmaceuticals Limited | P38 inhibitors |
| WO2009001204A2 (en) * | 2007-06-28 | 2008-12-31 | Cadila Pharmaceuticals Ltd. | Mitogen activated protein kinase modulator |
| WO2011083493A1 (en) * | 2010-01-08 | 2011-07-14 | National Institute Of Immunology | Human chorionic gonadotropin (hcg) based vaccine for prevention and treatment of cancer |
| US9795659B2 (en) * | 2010-02-19 | 2017-10-24 | Cadila Pharmaceuticals, Ltd. | Pharmaceutical composition of killed cells with substantially retained immunogenicity |
| MX340143B (es) * | 2010-10-13 | 2016-06-28 | Telesta Therapeutics Ip Inc | Composiciones de pared de célula de ácido ribonucléico bacterial y métodos para hacerlas y usarlas. |
| RU2580888C2 (ru) * | 2011-01-11 | 2016-04-10 | Кадила Фармасьютикалз Лимитед | Фармацевтическая композиция для лечения рака |
| TR201101874A2 (tr) * | 2011-02-25 | 2011-08-22 | Leyla A�An Nac�Ye | Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri. |
| WO2012117323A1 (en) * | 2011-02-28 | 2012-09-07 | Cadila Pharmaceuticals Limited | Therapeutic cancer vaccine |
| JP2014521599A (ja) * | 2011-07-05 | 2014-08-28 | カディラ ファーマシューティカルズ リミテッド | がん抗原 |
| US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5504005A (en) * | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| US6126945A (en) * | 1989-10-03 | 2000-10-03 | Pharmacia Ab | Tumor killing effects of enterotoxins, superantigens, and related compounds |
| IL105503A (en) * | 1992-04-28 | 1999-05-09 | Astra Ab | Carbon peptide couplets capable of eliciting an immune response of T cells |
| GB9223816D0 (en) * | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
| US5767156A (en) * | 1993-10-06 | 1998-06-16 | Peptide Technology Limited | Polyunsaturated fatty acids and uses thereof |
| US6090385A (en) * | 1993-12-10 | 2000-07-18 | Maes; Hubert | Method of treating cancer |
| GB9406301D0 (en) * | 1994-03-30 | 1994-05-25 | Univ London | Immunotherapeutic agent and its use |
| US6056964A (en) * | 1995-03-29 | 2000-05-02 | Stanford Rook Limited | Immunotherapeutic agent and its use |
| US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| US6080725A (en) * | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| US5869645A (en) * | 1997-10-15 | 1999-02-09 | Board Of Trustees Of The University Of Illinois | Method for isolating high molecular weight antineoplastic glycans using urea |
| AUPP437698A0 (en) * | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| WO2003075824A2 (en) * | 2002-03-08 | 2003-09-18 | Modi, Rajiv, Indravadan | Process of manufacturing pharmaceutical composition useful for management of tuberculosis |
-
2002
- 2002-10-12 UA UA20040705575A patent/UA79952C2/uk unknown
- 2002-12-10 JP JP2003550718A patent/JP4527979B2/ja not_active Expired - Fee Related
- 2002-12-10 CA CA2469266A patent/CA2469266C/en not_active Expired - Fee Related
- 2002-12-10 WO PCT/IB2002/005516 patent/WO2003049667A2/en not_active Ceased
- 2002-12-10 AU AU2002348738A patent/AU2002348738B2/en not_active Ceased
- 2002-12-10 US US10/502,417 patent/US7972609B2/en not_active Expired - Fee Related
- 2002-12-10 AP APAP/P/2004/003070A patent/AP1896A/en active
- 2002-12-10 GB GB0322773A patent/GB2389532C/en not_active Expired - Fee Related
- 2002-12-10 NZ NZ533417A patent/NZ533417A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005528332A5 (enExample) | ||
| JP2012530719A5 (enExample) | ||
| CN1102850C (zh) | 经皮吸收制剂 | |
| CN1298326C (zh) | 芬太尼经皮外用贴剂 | |
| RU2012148710A (ru) | Органическое соединение для применения при лечении рака печени | |
| NO20053782L (no) | Behandling av kreft med 2-deoksyglukose | |
| JP2010513500A5 (enExample) | ||
| AU2018260616B2 (en) | Treating and preventing kidney damage | |
| RU2009127500A (ru) | Фармацевтические композиции и способ лечения воспаления у крупного рогатого скота и других животных | |
| CN101068571A (zh) | 改善透粘膜给药制剂的吸收的方法 | |
| US20130149396A1 (en) | Silicate Containing Compositions and Methods of Treatment | |
| JP2001520656A (ja) | 抗腫瘍剤としてのホルボールエステル類 | |
| CN1668334A (zh) | 经皮吸收制剂 | |
| CN1154484C (zh) | 司来吉兰或去甲基司吉兰在生产治疗创伤、烧伤、光照损害的药物中的用途 | |
| JP2007534743A5 (enExample) | ||
| CN1149992C (zh) | 活性化合物高度释放的抗真菌凝胶 | |
| CN1795003A (zh) | 基于锶化合物的抗炎组合物 | |
| WO2005084387A3 (en) | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer | |
| CN1651433A (zh) | 一种丹酚酸黄连素复盐及其制备方法与应用 | |
| CN1468601A (zh) | 胡黄连苷ⅱ－一种用于治疗、预防过敏性炎性疾病的新药 | |
| JP2006528190A5 (enExample) | ||
| CN1555804A (zh) | 非那甾胺醇质体凝胶制剂 | |
| CN101401782A (zh) | 多拉菌素浇泼剂及其制备方法 | |
| CN1309125A (zh) | 具抗癌活性的藤黄酸类化合物的复合物及其制备方法 | |
| JP2006528185A5 (enExample) |